Concepedia

Author

Mat D. Davis

Teva Pharmaceuticals (United States)

Also Known As

Davis, Mat D., M Davis, M. Davis, M. Duff Davis, Mat D Davis, Mat D. Davis, Mat Davis

48

Publications

1.4K

Citations

14

H-Index

20

Concepts

All Affiliations

Teva Pharmaceuticals (United States)University of North Carolina at Chapel HillUniversity of PennsylvaniaHouston MethodistBanner Sun Health Research Institute
MD

About

Mat D. Davis is an author at Teva Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and cardiovascular disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

498

2

Health Sciences

1

1

47

3

Public Health

1

1

42

4

Epidemiology

1

1

42

5

Global Health

1

1

42

Mat D. Davis

×

15

Publications

1.3K

Citations

13

H-Index

YearCitations

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial

Karen E. Anderson, David Stamler, Mat D. Davis,

The Lancet Psychiatry

2017

326

Randomized controlled trial of deutetrabenazine for tardive dyskinesia

Hubert H. Fernandez, Stewart A. Factor, Robert A. Hauser,

Neurology

2017

322

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline

P. Murali Doraiswamy, Reisa A. Sperling, Robert E. Coleman,

Neurology

2012

228

Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals

Reisa A. Sperling, Keith A. Johnson, P. Murali Doraiswamy,

Neurobiology of Aging

2012

125

991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY

Mark Sulkowski, E. Läwitz, M. Shiffman,

Journal of Hepatology

2008

47

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia

Hubert H. Fernandez, David Stamler, Mat D. Davis,

Journal of Neurology Neurosurgery & Psychiatry

2019

47

Discordance between non-HDL-cholesterol and LDL-particle measurements: Results from the Multi-Ethnic Study of Atherosclerosis

Emil M. deGoma, Mat D. Davis, Richard L. Dunbar,

Atherosclerosis

2013

42

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study

Omar Khan, Peter Rieckmann, Krzysztof Selmaj,

Multiple Sclerosis Journal

2016

36

Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis

Zeke Campbell, DF Sahm, Katelyn Donohue,

Neurology

2012

26

Ring and nodular multiple sclerosis lesions

Mat D. Davis, Sungyoung Auh, Marco Riva,

Neurology

2010

22

Page 1